Complement Regulatory Genetic Mutations in the Setting of Autoimmune Thrombotic Thrombocytopenic Purpura: A Case Series

Objective: To explore the benefits of adding eculizumab for the treatment of refractory autoimmune thrombotic thrombocytopenic purpura (iTTP) with complement dysregulation. Patients and Methods: From January 1, 2014, through July 1, 2017, we identified patients with iTTP defined by ADAMTS13 (disinte...

Full description

Bibliographic Details
Main Authors: Shebli Atrash, MD, Appalanaidu Sasapu, MD, Soumya Pandey, MD, Michele Cottler-Fox, MD, Pooja Motwani, MD
Format: Article
Language:English
Published: Elsevier 2018-03-01
Series:Mayo Clinic Proceedings: Innovations, Quality & Outcomes
Online Access:http://www.sciencedirect.com/science/article/pii/S2542454817301285

Similar Items